Study Title and Description
Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection.
Key Questions Addressed
|8||Key Question 8 - Case studies/series and potential harms of nonstandard interventions for CDI|
Primary Publication Information
|Title||Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection.|
|Author||Herpers BL., Vlaminckx B., Burkhardt O., Blom H., Biemond-Moeniralam HS., Hornef M., Welte T., Kuijper EJ.|
|Country||Department of Medical Microbiology and Immunology, St. Antonius Hospital, PO Box 2500, Nieuwegein 3430 EM, The Netherlands. email@example.com|
Pubmed ID: 19435431
Secondary Publication Information
There are currently no secondary publications defined for this study.
Extraction Form: Key Question 4 - Case studies/series and potential harms of nonstandard interventions for CDI (Table C11)
|Question... Follow Up||Answer||Follow-up Answer|
|Study Focus||Treatment for severe refractory C. difficile infection|
|Subject/Study Details||4 patients with diarrhea, positive C. difficile toxin stool and pseudomembranes as well as septic or hypovolemic shock and other serious health problems 2 males, 59 and 36 years old and 2 females, 36 and 82 years old|
|Interventions||Intravenous tigecycline 100 mg x 1 dose then 50 mg twice/day for 7- 24 days 3 patients were treated with standard antibiotics along with tigecycline|
|Clinical Diarrhea Outcomes|
|C. difficile Toxin, C. difficile Culture, or Other||Clinical signs (e.g., diarrhea) improved within 7 d C. difficile toxin became negative in 3 patients within 7 d and after continued oral vancomycin in 1 patient in 2 weeks No recurrence was reported in 3 weeks|
|Adverse Effects (AE) Harms|
Results & Comparisons
No Results found.